Textron Free cash flow decreased by 147.4% to -$250.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 38.9%, from -$180.00M to -$250.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -6.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $128.00M | $516.00M | $325.00M | $254.00M | $193.00M | $306.00M | $270.00M | $365.00M | $101.00M | $213.00M | $179.00M | $371.00M | -$73.00M | $293.00M | $137.00M | $293.00M | -$180.00M | $309.00M | $273.00M | $527.00M | -$250.00M |
| QoQ Change | — | +303.1% | -37.0% | -21.8% | -24.0% | +58.5% | -11.8% | +35.2% | -72.3% | +110.9% | -16.0% | +107.3% | -119.7% | +501.4% | -53.2% | +113.9% | -161.4% | +271.7% | -11.7% | +93.0% | -147.4% |
| YoY Change | — | — | — | — | +50.8% | -40.7% | -16.9% | +43.7% | -47.7% | -30.4% | -33.7% | +1.6% | -172.3% | +37.6% | -23.5% | -21.0% | -146.6% | +5.5% | +99.3% | +79.9% | -38.9% |